Sökning: L773:0028 3878 OR L773:1526 632X >
Prepandemic Alzheim...
Prepandemic Alzheimer Disease Biomarkers and Anxious-Depressive Symptoms During the COVID-19 Confinement in Cognitively Unimpaired Adults
- Artikel/kapitelEngelska2022
Förlag, utgivningsår, omfång ...
-
2022-08-02
-
Ovid Technologies (Wolters Kluwer Health),2022
Nummerbeteckningar
-
LIBRIS-ID:oai:gup.ub.gu.se/322130
-
https://gup.ub.gu.se/publication/322130URI
-
https://doi.org/10.1212/wnl.0000000000200948DOI
Kompletterande språkuppgifter
Ingår i deldatabas
Klassifikation
-
Ämneskategori:ref swepub-contenttype
-
Ämneskategori:art swepub-publicationtype
Anmärkningar
-
Background and Objectives Increased anxious-depressive symptomatology is observed in the preclinical stage of Alzheimer disease (AD), which may accelerate disease progression. We investigated whether beta-amyloid, cortical thickness in medial temporal lobe structures, neuroinflammation, and sociodemographic factors were associated with greater anxious-depressive symptoms during the COVID-19 confinement. Methods This retrospective observational study included cognitively unimpaired older adults from the Alzheimer's and Families cohort, the majority with a family history of sporadic AD. Participants performed the Hospital Anxiety and Depression Scale (HADS) during the COVID-19 confinement. A subset had available retrospective (on average: 2.4 years before) HADS assessment, amyloid [F-18] flutemetamol PET and structural MRI scans, and CSF markers of neuroinflammation (interleukin-6 [IL-6], triggering receptor expressed on myeloid cells 2, and glial fibrillary acidic protein levels). We performed multivariable linear regression models to investigate the associations of prepandemic AD-related biomarkers and sociodemographic factors with HADS scores during the confinement. We further performed an analysis of covariance to adjust by participants' prepandemic anxiety-depression levels. Finally, we explored the role of stress and lifestyle changes (sleep patterns, eating, drinking, smoking habits, and medication use) on the tested associations and performed sex-stratified analyses. Results We included 921 (254 with AD biomarkers) participants. beta-amyloid positivity (B = 3.73; 95% CI = 1.1 to 6.36; p = 0.006), caregiving (B = 1.37; 95% CI 0.24-2.5; p = 0.018), sex (women: B = 1.95; 95% CI 1.1-2.79; p < 0.001), younger age (B = -0.12; 95% CI -0.18 to -0.052; p < 0.001), and lower education (B = -0.16; 95% CI -0.28 to -0.042; p = 0.008) were associated with greater anxious-depressive symptoms during the confinement. Considering prepandemic anxiety-depression levels, we further observed an association between lower levels of CSF IL-6 (B = -5.11; 95% CI -10.1 to -0.13; p = 0.044) and greater HADS scores. The results were independent of stress-related variables and lifestyle changes. Stratified analysis revealed that the associations were mainly driven by women. Discussion Our results link AD-related pathophysiology and neuroinflammation with greater anxious-depressive symptomatology during the COVID-19-related confinement, notably in women. AD pathophysiology may increase neuropsychiatric symptomatology in response to stressors. This association may imply a worse clinical prognosis in people at risk for AD after the pandemic and thus deserves to be considered by clinicians.
Ämnesord och genrebeteckningar
Biuppslag (personer, institutioner, konferenser, titlar ...)
-
Pena-Gomez, C.
(författare)
-
Operto, G.
(författare)
-
Fuentes-Julian, S.
(författare)
-
Deulofeu, C.
(författare)
-
Sanchez-Benavides, G.
(författare)
-
Mila-Aloma, M.
(författare)
-
Grau-Rivera, O.
(författare)
-
Gramunt, N.
(författare)
-
Navarro, A.
(författare)
-
Minguillon, C.
(författare)
-
Fauria, K.
(författare)
-
Suridjan, I.
(författare)
-
Kollmorgen, G.
(författare)
-
Bayfield, A.
(författare)
-
Blennow, Kaj,1958Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xbleka
(författare)
-
Zetterberg, Henrik,1973Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry(Swepub:gu)xzethe
(författare)
-
Molinuevo, J. L.
(författare)
-
Suarez-Calvet, M.
(författare)
-
Gispert, J. D.
(författare)
-
Arenaza-Urquijo, E. M.
(författare)
-
Alfa Study, Alfa Study
(författare)
-
Göteborgs universitetInstitutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi
(creator_code:org_t)
Sammanhörande titlar
-
Ingår i:NEUROLOGY: Ovid Technologies (Wolters Kluwer Health)99:140028-38781526-632X
Internetlänk
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
Akinci, M.
-
Pena-Gomez, C.
-
Operto, G.
-
Fuentes-Julian, ...
-
Deulofeu, C.
-
Sanchez-Benavide ...
-
visa fler...
-
Mila-Aloma, M.
-
Grau-Rivera, O.
-
Gramunt, N.
-
Navarro, A.
-
Minguillon, C.
-
Fauria, K.
-
Suridjan, I.
-
Kollmorgen, G.
-
Bayfield, A.
-
Blennow, Kaj, 19 ...
-
Zetterberg, Henr ...
-
Molinuevo, J. L.
-
Suarez-Calvet, M ...
-
Gispert, J. D.
-
Arenaza-Urquijo, ...
-
Alfa Study, Alfa ...
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Medicinska och f ...
-
och Neurovetenskaper
- Artiklar i publikationen
-
NEUROLOGY
- Av lärosätet
-
Göteborgs universitet